Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Medivir AB 

Lunastigen 7

Huddinge    141 44  Sweden
Phone: 46-8-608-3100 Fax: 46-8-608-3199




GlaxoSmithKline (North Carolina) 

Peptimmune, Inc.  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.

 Company News
Medivir AB (MVRBF)’s CEO Increases His Shareholding In The Company 1/27/2015 12:47:31 PM
Medivir AB (MVRBF) Makes Change Within The Management Team 1/21/2015 11:07:48 AM
Medivir AB (MVRBF): OLYSIO® Sales During The Fourth Quarter 2014 1/20/2015 11:35:30 AM
Medivir AB (MVRBF): MIV-802 Has Been Selected As A Candidate Drug And Enters Non-Clinical Development For The Treatment Of Hepatitis C Infection 12/22/2014 11:51:00 AM
Medivir AB (MVRBF): Interim Report, January – September 2014 11/20/2014 11:35:40 AM
Johnson & Johnson (JNJ), Medivir AB (MVRBF) Snags U.S. Approval For Hepatitis C Combo With Gilead Sciences, Inc. (GILD) 11/6/2014 6:10:50 AM
Medivir AB (MVRBF) And County Councils Conclude Agreement On Olysio®-Based Treatment For Hepatitis C 10/30/2014 9:55:10 AM
Notice Of Extraordinary General Meeting Of Medivir AB (MVRBF) (Publ) 10/23/2014 11:55:35 AM
Medivir AB (MVRBF): Optimization Of Capital Structure 10/16/2014 1:53:36 PM
Medivir AB (MVRBF): Phase 2 IMPACT Study Initiated To Evaluate Simeprevir In Combination With Sofosbuvir And Daclatasvir To Treat Genotype 1 And 4 Hepatitis C Patients 10/10/2014 8:33:57 AM